Advaxis, Inc.
Fifteen Percent of ADXS11-001 Treated Cervix Cancer Patients Still Alive Three Years after Initial Dosing
Published in Women's Health Law Weekly, January 17th, 2010
The Phase I trial of ADXS11-001, the lead vaccine candidate of Advaxis, Inc., (OTCBB: ADXS), the company that pioneered the live, attenuated Listeria monocytogenes (Lm) vaccine, has shown thirty-six (36) month survival in two (2) of the thirteen (13) evaluable patients treated with Advaxis' therapeutic cancer vaccine, indicating the possibility of persistent immune protection, from only a two (2) dose initial regimen.
The patients had participated in the first human trial of a live Listeria vaccine for the treatment of advanced, recurrent, metastatic cervix cancer in women who have failed prior cytotoxic treatment. Advaxis is tracking the survival of these patients at...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Law Weekly
More Articles from Women's Health Law Weekly
- Coalition for Pulmonary Fibrosis
Coalition for Pulmonary Fibrosis Celebrates Successes Despite Year of Economic Downturn - Life Sciences
New data from University of Heidelberg illuminate research in life sciences - Opportunistic Infections
Research conducted at Alfred Hospital has updated our knowledge about opportunistic infections - A.A.C. Forearm Forklift, Inc.
Lifting Straps Turn PINK to Help Cure Breast Cancer - Age and Aging
New age and aging study results reported from University of Bologna, Department of Experimental Pathology - Ameloblastoma
New ameloblastoma findings from Q. Tao and co-authors described - More from this issue of Women's Health Law Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
